Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immune Therapeutics, Inc. (IMUN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.6500-0.1000 (-5.71%)
At close: 02:11PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7500
Open1.6500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.6500 - 1.6500
52 Week Range1.0200 - 5.3500
Volume301
Avg. Volume251
Market Cap795,144
Beta (5Y Monthly)1.01
PE Ratio (TTM)0.29
EPS (TTM)5.7020
Earnings DateJun 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer

    ORLANDO, FL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Glen Farmer as Chief Financial Officer and Kelly Wilson as Chief Operating Officer. Mr. Farmer will be replacing Dr. Stephen Wilson who was serving as t

  • GlobeNewswire

    Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer

    ORLANDO, FL, July 22, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development and commercialization of pharmaceutical and biotechnology products that have a short and well-defined path to market, is pleased to announce the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he w

  • GlobeNewswire

    Immune Therapeutics, Inc. Announces Expansion of its Board of Directors

    ORLANDO, Fla, June 03, 2022 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced that it will expand its Board of Directors from two to five members. Joining the Board effective May 31st, 2022, will be Dr. Stephen Wilson, Dr.

Advertisement
Advertisement